How many patents does
Aventis Pharma have?
patents
3,215
families
451
granted
985
applications
2,230
US
362
EP
264
CN
137
JP
70
KR
40
WO
34
RoW
2,308
Buy the report
The report contains ten-year analysis with the following sections
- patent filing analysis
- worldwide filing analysis
- patent family analysis
- application analysis
- granted analysis
- classification analysis
- citation analysis
contact us for pricing
- VAT will apply to UK companies
- EU companies must supply their VAT number
Check out our sample pages |
Find companies to compare
Many companies now available
companies
12,000+
patents
42 million
patent families
23 million
Search to find companies of interest
read summary of their published patent
the following tables are just extracts from the report
the company report contains more information
Aventis Pharma
Top ten assignees appearing on patents
2009 - 2018
| aventis pharma | 2442 |
| sanofi | 153 |
| sanofi-aventis deutschland | 134 |
| novexel | 67 |
| centelion | 63 |
| crouzet, joel | 28 |
| rhone-poulenc rorer | 28 |
| aventis holdings | 21 |
| aventisub ii | 21 |
| aventis pharma deutschland | 20 |
2009
| aventis pharma | 646 |
| sanofi-aventis deutschland | 30 |
| centelion | 26 |
| novexel | 19 |
| sanofi | 11 |
| aventis holdings | 6 |
| aventis pharma deutschland | 6 |
| rhone-poulenc rorer | 6 |
| mercken, luc | 5 |
| hmr pharma | 4 |
2018
| sanofi | 47 |
| aventis pharma | 23 |
| aventisub | 1 |
| pfizer ireland pharmaceuticals | 1 |
Aventis Pharma
The top ten patent families are
|
Title of patent family (most common patent title) |
Family members |
Filing year |
|---|---|---|
| antibodies that bind il-4 and/or il-13 and their uses | 171 | 2007 |
| formas cristalinas del dimetoxi-docetaxel y sus procedimientos de preparacion | 71 | 2008 |
| method for measuring resistance or sensitivity to docetaxel | 69 | 2004 |
| cholesterol-producing yeast strains and uses thereof | 45 | 2004 |
| novel antitumoral use of cabazitaxel | 43 | 2009 |
| pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and / … 🛈 | 42 | 1999 |
| heterocyclic compounds which are active as inhibitors of beta lactamases | 42 | 2002 |
| novel taxoid-based compositions | 39 | 2007 |
| modified soluble fgf receptor fc fusions with improved biological activity | 38 | 2006 |
| antitumour combinations containing a vegf inhibiting agent and irinotecan | 36 | 2007 |